期刊文献+

贝伐珠单抗联合培美曲塞加卡铂新辅助化疗方案对Ⅲa期肺腺癌手术安全的影响 被引量:13

下载PDF
导出
摘要 目的探究贝伐珠单抗联合培美曲塞加卡铂新辅助化疗方案对Ⅲa期肺腺癌手术安全的影响。方法回顾性分析我院收治的37例Ⅲa期肺腺癌手术患者于术前予以贝伐珠单抗与培美曲塞加卡铂的临床资料,分析新辅助化疗方案对Ⅲa期肺腺癌手术安全性的影响。结果 37例患者化疗毒性反应发生率为91. 9%,其中,Ⅲ~Ⅳ级毒性反应发生率为29. 7%。术后30 d内并发症发生率为18. 9%,术后60 d内并发症发生率为2. 7%。结论于Ⅲa期肺腺癌手术术前,应用贝伐珠单抗联合新辅助化疗方案治疗,未发生严重药物毒副反应,患者均可耐受,手术安全性较高。
出处 《解放军预防医学杂志》 CAS 2019年第4期126-127,共2页 Journal of Preventive Medicine of Chinese People's Liberation Army
基金 江苏省中医药局科技项目(No.YB2015123)
  • 相关文献

参考文献5

二级参考文献21

  • 1Azzoli CG, Baker S Jr, Temin S, Pao W, Aliff T, Brahmer J, Johnson DH, Laskin JL, Masters G, Milton D, Nordquist L, Pfister DG, Piantadosi S, Schiller JH, Smith R, Smith TJ, Strawn JR, Trent D, Giaccone G; American Society of Clinical Ontology. American Society of Clinical Oneology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol, 2009, 27 (36) : 6251-6266.
  • 2D'Addario G, Felip E; ESMO Guidelines Working Group. Non- small-cell lung cancer: ESMO clinical recommendations for diag- nosis, treatment and follow-up. Ann Oneol, 2009, 20 ( Suppl4) : 68-70.
  • 3Sandier A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med, 2006, 355 (24): 2542-2550.
  • 4Kurishima K, Ohara G, Kagohashi K, Takayashiki N, Tamura T, Shiozawa T, Miyazaki K, Kawaguchi M, Satoh H, Hizawa N. Ossification and increased bone mineral density with zoledronic acid in a patient with lung adenoearcinorca: a ease report. Exp T- her Med, 2014, 8 (4): 1267-1270.
  • 5Man Y, Can J, Jin S, Xu G, Pan B, Shang L, Che D, Yu Q, Yu Y. Newly identified biorcarkers for detecting circulating tumor cells in lung adenocarcinoma. Tohoku J Exp Med, 2014, 234 (1): 29-40.
  • 6Han HS, Son SM, Yun J, Jo YN, Lee OJ. MicroRNA-29a sup- presses the growth, migration, and invasion of lung adenocarcino- ma cells by targetingearcinoembryonic antigen-related cell adhe- sion molecule 6. FEBS Lett, 2014, 588 (20) : 3744-3750.
  • 7Hu H, Pan Y, Li Y, Wang L, Wang R, Zhang Y, Li H, Ye T, Zhang Y, Luo X, Shao L, Sun Z, Cai D, Xu J, Lu Q, Deng Y, Shen L, Ji H, Sun Y, Chen H. Oncogenic mutations are associ- ated with histological subtypes but do not have an independent prognostic value in lung adenocarcinom~ Onco Targets Ther, 2014, 13 (7): 1423-1437.
  • 8de Souza LR, Muehlmann LA, Dos Santos MS, Ganassin R, Sim6n-V6zquez R, Joanitti GA, Mosiniewicz-Szablewska E, Su- chocki P, Morais PC, Gonzalez-Fernandez ~, Azevedo RB, B6o SN. PVM/MA-shelled selol nanocapsules promote cell cycle arrest in A549 lung adenocarcinoma cells. J Nanobiotechnology, 2014, 12 (1): 32.
  • 9陈筱玲,方健.贝伐珠单抗在非小细胞肺癌中应用的研究现状[J].中国肿瘤临床,2011,38(12):747-750. 被引量:12
  • 10赵静,李航,张力,钟巍,李龙芸,文煜冰,王孟昭.四例贝伐单抗所致肾损害临床和病理特征分析[J].中国医学科学院学报,2012,34(2):153-158. 被引量:9

共引文献88

同被引文献131

引证文献13

二级引证文献53

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部